Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H. Nagato T, et al. Among authors: takahara m. Cancer Immunol Immunother. 2017 Jul;66(7):877-890. doi: 10.1007/s00262-017-1987-x. Epub 2017 Mar 27. Cancer Immunol Immunother. 2017. PMID: 28349165 Free PMC article.
Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma.
Nagato T, Ueda S, Takahara M, Kishibe K, Komabayashi Y, Kumai T, Ohara K, Hirata-Nozaki Y, Harabuchi S, Hayashi R, Ohkuri T, Bernasconi M, Nadal D, Kobayashi H, Harabuchi Y. Nagato T, et al. Among authors: takahara m. Lab Invest. 2019 May;99(5):612-624. doi: 10.1038/s41374-018-0182-9. Epub 2019 Jan 21. Lab Invest. 2019. PMID: 30664711 Free article.
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H. Hayashi R, et al. Among authors: takahara m. Oncoimmunology. 2020 Dec 29;10(1):1856545. doi: 10.1080/2162402X.2020.1856545. Oncoimmunology. 2020. PMID: 33457076 Free PMC article.
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery.
Kono M, Kumai T, Hayashi R, Yamaki H, Komatsuda H, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Kobayashi H, Harabuchi Y. Kono M, et al. Among authors: takahara m. Cancer Immunol Immunother. 2021 Dec;70(12):3421-3434. doi: 10.1007/s00262-021-02940-5. Epub 2021 Apr 18. Cancer Immunol Immunother. 2021. PMID: 33866408 Free PMC article.
874 results